PMC:7306567 / 2318-3045 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":146,"end":156},"obj":"Body_part"},{"id":"T4","span":{"begin":172,"end":176},"obj":"Body_part"},{"id":"T5","span":{"begin":466,"end":470},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62860"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"53","span":{"begin":516,"end":541},"obj":"Disease"},{"id":"46","span":{"begin":710,"end":719},"obj":"Chemical"},{"id":"47","span":{"begin":0,"end":32},"obj":"Disease"},{"id":"48","span":{"begin":113,"end":134},"obj":"Disease"},{"id":"49","span":{"begin":146,"end":184},"obj":"Disease"},{"id":"50","span":{"begin":338,"end":360},"obj":"Disease"},{"id":"51","span":{"begin":418,"end":432},"obj":"Disease"},{"id":"52","span":{"begin":434,"end":436},"obj":"Disease"}],"attributes":[{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:C551803"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D055744"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D009503"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:C563515"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D055744"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D015470"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D009101"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D006086"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T21","span":{"begin":19,"end":32},"obj":"Disease"},{"id":"T22","span":{"begin":123,"end":134},"obj":"Disease"},{"id":"T23","span":{"begin":338,"end":360},"obj":"Disease"},{"id":"T24","span":{"begin":347,"end":360},"obj":"Disease"},{"id":"T25","span":{"begin":362,"end":364},"obj":"Disease"},{"id":"T26","span":{"begin":418,"end":432},"obj":"Disease"},{"id":"T27","span":{"begin":424,"end":432},"obj":"Disease"},{"id":"T28","span":{"begin":434,"end":436},"obj":"Disease"},{"id":"T29","span":{"begin":516,"end":541},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0010643"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0010643"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0013730"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":42,"end":43},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T16","span":{"begin":170,"end":176},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T17","span":{"begin":466,"end":470},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T18","span":{"begin":721,"end":725},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":34,"end":37},"obj":"Chemical"},{"id":"T6","span":{"begin":362,"end":364},"obj":"Chemical"},{"id":"T7","span":{"begin":434,"end":436},"obj":"Chemical"},{"id":"T8","span":{"begin":552,"end":562},"obj":"Chemical"},{"id":"T9","span":{"begin":710,"end":719},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_74062"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_73770"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_76612"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":0,"end":32},"obj":"Phenotype"},{"id":"T7","span":{"begin":34,"end":37},"obj":"Phenotype"},{"id":"T8","span":{"begin":123,"end":134},"obj":"Phenotype"},{"id":"T9","span":{"begin":418,"end":432},"obj":"Phenotype"},{"id":"T10","span":{"begin":434,"end":436},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0001875"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002488"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002488"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T20","span":{"begin":0,"end":305},"obj":"Sentence"},{"id":"T21","span":{"begin":306,"end":607},"obj":"Sentence"},{"id":"T22","span":{"begin":608,"end":727},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T29","span":{"begin":9,"end":18},"obj":"UBERON:0002048"},{"id":"T30","span":{"begin":96,"end":107},"obj":"NCBITaxon:1"},{"id":"T31","span":{"begin":146,"end":156},"obj":"CL:0000775"},{"id":"T32","span":{"begin":170,"end":176},"obj":"CL:0000084"},{"id":"T33","span":{"begin":275,"end":292},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T34","span":{"begin":710,"end":719},"obj":"CHEBI:76612;CHEBI:76612"},{"id":"T81322","span":{"begin":9,"end":18},"obj":"UBERON:0002048"},{"id":"T51311","span":{"begin":96,"end":107},"obj":"NCBITaxon:1"},{"id":"T81106","span":{"begin":146,"end":156},"obj":"CL:0000775"},{"id":"T17383","span":{"begin":170,"end":176},"obj":"CL:0000084"},{"id":"T96288","span":{"begin":275,"end":292},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T80755","span":{"begin":710,"end":719},"obj":"CHEBI:76612;CHEBI:76612"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"2_test","denotations":[{"id":"32572532-25354514-47963394","span":{"begin":302,"end":303},"obj":"25354514"},{"id":"32572532-29437588-47963395","span":{"begin":721,"end":722},"obj":"29437588"},{"id":"T48775","span":{"begin":302,"end":303},"obj":"25354514"},{"id":"T15892","span":{"begin":721,"end":722},"obj":"29437588"}],"text":"Invasive pulmonary aspergillosis (IPA) is a well-recognized disease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Patients at the highest risk of invasive aspergillosis (IA) include those undergoing intensive chemotherapy for acute leukemia (AL) or recipients of allogeneic cell transplantation (alloHCT) who develop severe graft-versus-host disease, for whom antifungal prophylaxis is currently recommended [2, 3]. With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}